Skip to Content

Syrrx is transforming the landscape of drug discovery with a dedicated focus on developing breakthrough therapies for cancer, metabolic diseases, and inflammation. Leveraging cutting-edge structural biology and medicinal chemistry, Syrrx is pioneering new approaches to drug design by precisely monitoring how drug candidates bind to their specific protein targets. This unique approach allows Syrrx to create highly selective and potent drug candidates with the potential to address unmet medical needs across a variety of diseases.


Since its founding in 1999, Syrrx has made remarkable strides toward its mission of becoming a leading company in structure-based drug discovery. By early 2001, Syrrx launched its high-throughput structural biology operations, setting a strong foundation for future advancements. Some of the company’s major milestones to date include:

  • Advancement of Lead Candidates: Syrrx has demonstrated successful animal efficacy data for two lead drug candidates and is on track to initiate clinical studies by 2004, marking a significant step in its drug development journey.
  • Strategic Partnerships: Syrrx entered a pivotal partnership with PPD, Inc., for the clinical development of its DPP IV program. This collaboration provided Syrrx with a $25 million investment, milestone payments, and a substantial 50% share in the profits from future drug sales. Additionally, Syrrx formed a strategic alliance with Roche to explore novel drug candidates targeting cancer and type II diabetes, reinforcing its commitment to advancing therapies in high-impact therapeutic areas.
  • Collaborative Successes: Syrrx's collaboration with Biogen Idec concluded successfully, resulting in three success-based milestone payments, reflecting the productive nature of this partnership and the potential impact of Syrrx’s research on the industry.
  • Assembling Top Talent: The company has recruited a team of world-class executives and drug discovery experts, many of whom have contributed to the structure-based design of leading marketed drugs, including Viracept™. Syrrx has also built a chemistry team composed of top professionals with extensive experience in drug discovery from renowned organizations like Pfizer, GSK, Abbott, and Celera.
  • Innovative Technology and Infrastructure: Syrrx pioneered the world’s first Nanovolume Crystallization® technology, a breakthrough that enhances the efficiency of the crystallization process crucial to structural biology. Additionally, the company secured an 84,000 square foot facility, equipped with state-of-the-art biology, chemistry, analytical, and crystallography labs, and a powerful Linux-based supercomputer, all of which support its high-throughput structural biology work.
  • Key Scientific Achievements: To date, Syrrx has successfully solved over 140 unique structures, including groundbreaking structures of critical kinases like AKT-3 and FAK, and proteases such as HDAC and DP4. These achievements provide valuable insights that drive the design of novel therapies targeting complex diseases.
  • Financial Growth and Intellectual Property: Syrrx has completed six Series Preferred rounds of financing, raising over $135 million, which has allowed the company to fund its innovative research and expand its capabilities. Furthermore, Syrrx has built a robust intellectual property portfolio with over 105 pending patent applications, establishing a strong foundation for the protection and commercialization of its discoveries.

As Syrrx continues to grow, its focus remains on discovering new treatments that could significantly improve patient outcomes, backed by a commitment to innovation, collaboration, and scientific excellence. Through its pioneering research and partnerships, Syrrx is poised to make substantial contributions to the biotech and pharmaceutical industries, bringing hope to millions of patients worldwide.